161 related articles for article (PubMed ID: 38706271)
1. Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies.
Prins ND; de Haan W; Gardner A; Blackburn K; Chu HM; Galvin JE; Alam JJ
J Prev Alzheimers Dis; 2024; 11(3):549-557. PubMed ID: 38706271
[TBL] [Abstract][Full Text] [Related]
2. Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies.
Alam JJ; Maruff P; Doctrow SR; Chu HM; Conway J; Gomperts SN; Teunissen C
Neurology; 2023 Oct; 101(17):e1708-e1717. PubMed ID: 37657939
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.
Prins ND; Harrison JE; Chu HM; Blackburn K; Alam JJ; Scheltens P;
Alzheimers Res Ther; 2021 May; 13(1):106. PubMed ID: 34044875
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration.
Jiang Y; Alam JJ; Gomperts SN; Maruff P; Lemstra AW; Germann UA; Stavrides PH; Darji S; Malampati S; Peddy J; Bleiwas C; Pawlik M; Pensalfini A; Yang DS; Subbanna S; Basavarajappa BS; Smiley JF; Gardner A; Blackburn K; Chu HM; Prins ND; Teunissen CE; Harrison JE; Scheltens P; Nixon RA
Nat Commun; 2022 Sep; 13(1):5308. PubMed ID: 36130946
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic differences based on staging of Alzheimer's neuropathology in autopsy-confirmed dementia with Lewy bodies.
Peavy GM; Edland SD; Toole BM; Hansen LA; Galasko DR; Mayo AM
Parkinsonism Relat Disord; 2016 Oct; 31():72-78. PubMed ID: 27475955
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study.
McKeith I; O'Brien J; Walker Z; Tatsch K; Booij J; Darcourt J; Padovani A; Giubbini R; Bonuccelli U; Volterrani D; Holmes C; Kemp P; Tabet N; Meyer I; Reininger C;
Lancet Neurol; 2007 Apr; 6(4):305-13. PubMed ID: 17362834
[TBL] [Abstract][Full Text] [Related]
7. A Longitudinal Study of Plasma pTau181 in Mild Cognitive Impairment with Lewy Bodies and Alzheimer's Disease.
Thomas AJ; Hamilton CA; Heslegrave A; Barker S; Durcan R; Lawley S; Barnett N; Lett D; Firbank M; Roberts G; Taylor JP; Donaghy PC; Zetterberg H; O'Brien J
Mov Disord; 2022 Jul; 37(7):1495-1504. PubMed ID: 35318733
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load.
Del Ser T; Hachinski V; Merskey H; Munoz DG
Alzheimer Dis Assoc Disord; 2001; 15(1):31-44. PubMed ID: 11236823
[TBL] [Abstract][Full Text] [Related]
9. Neuropsychiatric symptoms and cognitive profile in mild cognitive impairment with Lewy bodies.
Donaghy PC; Taylor JP; O'Brien JT; Barnett N; Olsen K; Colloby SJ; Lloyd J; Petrides G; McKeith IG; Thomas AJ
Psychol Med; 2018 Oct; 48(14):2384-2390. PubMed ID: 29362011
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
[TBL] [Abstract][Full Text] [Related]
11. Severity of cognitive impairment and the clinical diagnosis of AD with Lewy bodies.
Lopez OL; Hamilton RL; Becker JT; Wisniewski S; Kaufer DI; DeKosky ST
Neurology; 2000 May; 54(9):1780-7. PubMed ID: 10802784
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Plasma pTau181 Predicts Clinical Progression in a Phase 2 Randomized Controlled Trial of the 11β-HSD1 Inhibitor Xanamem® for Mild Alzheimer's Disease.
Taylor J; Jaros M; Chen C; Harrison J; Hilt D
J Alzheimers Dis; 2024; 100(1):139-150. PubMed ID: 38848180
[TBL] [Abstract][Full Text] [Related]
14. Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression.
van de Beek M; van Steenoven I; van der Zande JJ; Barkhof F; Teunissen CE; van der Flier WM; Lemstra AW
Mov Disord; 2020 May; 35(5):859-867. PubMed ID: 32048343
[TBL] [Abstract][Full Text] [Related]
15. Predicting the time to clinically worsening in mild cognitive impairment patients and its utility in clinical trial design by modeling a longitudinal clinical dementia rating sum of boxes from the ADNI database.
Ito K; Hutmacher MM
J Alzheimers Dis; 2014; 40(4):967-79. PubMed ID: 24531162
[TBL] [Abstract][Full Text] [Related]
16. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
Rolinski M; Fox C; Maidment I; McShane R
Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
[TBL] [Abstract][Full Text] [Related]
17. Dementia with Lewy bodies: diagnosis and management.
Barber R; Panikkar A; McKeith IG
Int J Geriatr Psychiatry; 2001 Dec; 16 Suppl 1():S12-8. PubMed ID: 11748785
[TBL] [Abstract][Full Text] [Related]
18. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.
Emre M; Tsolaki M; Bonuccelli U; Destée A; Tolosa E; Kutzelnigg A; Ceballos-Baumann A; Zdravkovic S; Bladström A; Jones R;
Lancet Neurol; 2010 Oct; 9(10):969-77. PubMed ID: 20729148
[TBL] [Abstract][Full Text] [Related]
19. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies.
McCleery J; Morgan S; Bradley KM; Noel-Storr AH; Ansorge O; Hyde C
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010633. PubMed ID: 25632881
[TBL] [Abstract][Full Text] [Related]
20. Cognitive Function Remains Associated With Functional Impairment in Profound Dementia: Alzheimer Disease and Dementia With Lewy Bodies.
Rampalli I; Pavlik VN; Yu MM; Bishop J; Lin CR
Neurol Clin Pract; 2024 Apr; 14(2):e200262. PubMed ID: 38322828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
